A 12-week open-label followed by 4-week double-blind study to determine the safety and efficacy of an extended course of alefacept (LFA-3/igg1 fusion protein) in subjects with chronic plaque psoriasis

Autor:	Robin R. Blum, Mark Lebwohl, Carin H. Gribetz, Steven R. Cohen
Rok vydání:	2004
Předmět:	Double blind study medicine.medical_specialty business.industry Internal medicine medicine Dermatology Open label business Alefacept medicine.drug
Zdroj:	Journal of the American Academy of Dermatology. 50:P141
ISSN:	0190-9622
DOI:	10.1016/j.jaad.2003.10.490
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e72a92ca20ba7173a9841ffad8849ef5 https://doi.org/10.1016/j.jaad.2003.10.490 Zobrazit plný text záznamu Full Text from ScienceDirect